02/06/2026 – Stonegate Capital Partners updates its coverage of AB Science’s stock with a discounted cash flow valuation mid-point of EUR 4.25 per share Download PDF Post navigationPreviousPrevious post:AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per shareNextNext post:AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALSRelated PostsAB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026Annual financial results as of 31 December, 202513 May 2026AB Science announces the successful completion of a EUR 3.2 million private placement29 April 2026AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
